SynthesisMedicine2017
Association between ALDH2 Glu487Lys polymorphism and the risk of esophageal cancer.
Synthesis in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 13 citations in OpenAlex.
- ALDH2 protects against dopaminergic neuronal cell ferroptosis by enhancing the enzyme activity of PRDX6 in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Physiologic and molecular effects of alcohol in the esophagus: a narrative review.Annals of esophagus · 2025Article
- In Vitro Evaluation of ALDH1A3-Affinic Compounds on Breast and Prostate Cancer Cell Lines as Single Treatments and in Combination with Doxorubicin.Current issues in molecular biology · 2023Article
- Gene and cell therapy on the acquisition and relapse-like binge drinking in a model of alcoholism: translational options.Gene therapy · 2019Review
- Observational
- Association ofOncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveA meta-analysis was carried out to further evaluate the relationship between ALDH2 Glu487Lys polymorphism and esophageal cancer risk.
methodsA total number of 15 studies that included 3812 cases and 7376 controls were identified for our meta-analysis.
resultsOur findings indicated that individuals with the combination of Glu/Lys and Lys/Lys genotype had an increased risk of getting esophageal cancer (GA + AA vs. GG: odds ratio [OR] 1.36, 95% confidence interval [CI] 0.93-2.00, P = 0.113) with a shift pattern. Although Lys/Lys genotype carriers showed areduced esophageal cancer risk (AA vs. GA + GG: OR 0.41, 95% CI 0.23-0.72, P = 0.002). Similarly, a negative association was observed under homozygote comparison (AA vs. GG: OR 0.49, 95% CI 0.29-0.85, P = 0.011). In the China subgroup analysis, the similar results were found.
conclusionsThis meta-analysis concluded that there was a strong association between ALDH2 Glu487Lys polymorphism and the risk of esophageal cancer. It further confirmed that ALDH2 Glu487Lys polymorphism was a high-risk factor for esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.